Search results for "SLI"
showing 10 items of 1729 documents
Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma.
2009
Background The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice. Objective To compare the different economic relevance, over a long evaluation time, of symptomatic pharmacologic therapy and sublingual immunotherapy (SLIT) in patients with allergic asthma. Methods Seventy patients with perennial allergic asthma, sensitized to dust mites, were enrolled; 50 of these patients were treated with SLIT against house dust mites and 20 were treated with symptomatic drugs. The patients were evaluated for …
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic…
2018
Reslizumab is a humanized anti-IL-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.To predict response and nonresponse to intravenous reslizumab at 52 weeks with an algorithm we developed based on clinical indicators from pivotal clinical trials.Patients aged 18 years and older who met Global Initiative for Asthma 4 or 5 criteria and received intravenous reslizumab (n = 321) in two trials ( www.clinicaltrials.gov identifiers, NCT01287039 and NCT01285323) were selected as the data source. A mathematical model was constructed that was based on change from baseline to 16 weeks in Asthma Control Questionnaire and Asthma Quality of Lif…
Tablet-based sublingual immunotherapy for respiratory allergy
2017
Allergic respiratory disease represents a significant and expanding health problem worldwide. The gold standard of therapeutic intervention is still grucocorticosteroids, although they are not effective in all patients and may cause side effects. Allergen Immunotherapy has been administrated as subcutaneous injections for treatment of allergic rhinoconjunctivitis and asthma and has been practiced for the past century. Sublingual immunotherapy (SLIT) tablets are now available for grass- or ragweed-induced rhinoconjunctivitis and will be available in Spain for house dust mite (HDM)-induced rhinoconjunctivitis and asthma in the next months. In this review, new developments in the field of tabl…
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
2019
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma. However, while OCS are effective at treating acute exacerbations, there is only empirical evidence regarding the efficacy of OCS at reducing the rate of exacerbations. Evidence, although scarce, is suggestive of high exacerbation rates in severe asthma patients even when receiving maintenance treatment with OCS. In addition, use of OCS is associated with undesirable effects. Despite all this, physicians have continued to use OCS for managing severe asthma and acute exacerbation due to the lack of availability of effective…
Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics
2019
Background: Healthcare decisions made on the basis of insufficient evidence may potentially have ineffective or even harmful consequences. The proportion of older ages (over 65 years) in randomized controlled trials (RCTs) for severe asthma is not enough to establish whether anti-IL-5/IL-5R therapies are equally effective in the elderly as in younger subjects. Methods: In order to assess the relationship between age and the efficacy of anti-IL-5 monoclonal antibodies (mABs) with respect to the risk of exacerbations and changes in FEV1, a meta-regression analysis via random-effect method was carried out by plotting the effect estimates (outcome variables) resulting from the pairwise meta-ana…
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
2017
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This secondary analysis assessed reslizumab's efficacy in patients receiving baseline treatment per Global Initiative for Asthma (GINA) Step 4 and Step 5 guidelines. Pooled data from duplicate, Phase III, reslizumab versus placebo studies in patients with severe eosinophilic asthma (blood eosinophils ≥400 cells·µL−1) were stratified by baseline therapy. Efficacy assessments were exacerbation rates and changes from baseline forced expiratory volume in …
Care pathways for the selection of a biologic in severe asthma.
2017
Physicians need care pathways to select a biologic in type 2 severe asthma (omalizumab, mepolizumab, reslizumab) http://ow.ly/pygw30gB7Bv
<p>Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma</p>
2020
Background Anti-IL-5 antibodies represent an established therapy for severe eosinophilic asthma (SEA), but some patients show inadequate response. The objective of this study was to assess the effects of a switch to anti-IL-5Rα therapy in patients with inadequate response to anti-IL-5 therapy. Methods In this retrospective multi-centre, real-life study, we analysed all SEA patients switched from anti-IL-5 to anti-IL-5Rα therapy due to inadequate response or intolerability. Pulmonary function tests, blood gas analyses, asthma control tests (ACT) and oral corticosteroid (OCS) usage were analysed and compared at three timepoints: baseline (BL, before anti-IL-5 therapy), timepoint 1 (T1, under …
Zvaigžņotā Debess: 2011/12, Ziema (214)
2011
Saturs: Gamma staru astronomijas problēmas ; Apollo-14 Mēness ekspedīcija ; A.Laure. Protoplanetāro miglāju stadija zvaigžņu evolūcijā ; A.A. Jaunumi īsumā: Oglekļa zvaigzne un rentgenstaru avots ; A.Alksnis. Heršels ielūkojas Miras galvā ; D.Docenko. Jauns dziļš debess apskats WiggleZ ir pabeigts: gaidām rezultātus ; A.A. Jaunumi īsumā: Pundurplanēta Erīda ir precīzi izmērīta. Atvērto durvju dienā Garhingā... ; M.Gertāns. Iepazīstot Kenedija kosmosa centru un atvadoties no Space Shuttle ; J.Dambītis. Ievērojams Latvijas matemātiķis – docents Nikolajs Brāzma (1913-1966) ; J.Jansons. Fiziķu centieni 1950.-1960. gados atgriezt fundamentālo zinātni Universitātē ; V.Fļorovs, A.Cēbers, D.Bočarov…
A new proof of the support theorem and the range characterization for the Radon transform
1983
The aim of this note is to give a new and elementary proof of the support theorem for the Radon transform, which is based only on the projection theorem and the Paley-Wiener theorem for the Fourier transform. The idea is to solve a certain system of linear equations in order to determine the coefficients of a homogeneous polynomial (interpolation problem). By the same method, we get a short proof of the range characterization for Radon transforms of functions supported in a ball.